Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Immunome Q3 2026 Results: Net Loss of $85.8M, Loss Widens

Immunome Inc. reported a net loss of $212.4 million for 2025, an improvement from $293.0 million in 2024, primarily due to a significant decrease in in-process research and development expenses. The company significantly strengthened its liquidity position, ending 2025 with $653.5 million in cash and cash equivalents following two major public offerings that raised over $594 million in net proceeds.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-85.8-57.5
EPS (diluted, $ a share)$-0.76$-0.65

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: IMNM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Immunome Inc.: key numbers

Share price
$17.61Close, Nov 16
Market cap
$2.08B
Shares outstanding
118.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Immunome Inc.

All →
4:06 PM ET 8-K
Financial Results

Immunome Financial Results

Immunome reported third quarter 2026 financial results and provided a pipeline update, highlighting an FDA PDUFA date of April 28, 2027, for varegacestat. The company also announced IND clearance for its solid tumor ADC candidate IM-1340 and plans to initiate a Phase 1 trial by year-end 2026.

Term
Q3 2026

“We made significant progress across our oncology pipeline in recent months. We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA. Beyond varegacestat, we now have three programs in the clinic, with IM-1340 expected to become the fourth by year-end. We are progressing the Phase 1 study of IM-1021, our ROR1-targeted ADC, and look forward to presenting updated Phase 1 data at ASH in December.”

Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome
8:30 AM ET 8-K
Other 8-K Filing

Immunome Other 8-K Filing

Immunome entered into an amendment with Bristol-Myers Squibb (BMS) to eliminate all future milestone and royalty payment obligations related to varegacestat and AL101. In exchange, Immunome paid BMS $20 million in cash and issued approximately 4.4 million shares of common stock, while also gaining full ownership of the related patent rights.

Counterparty
Bristol-Myers Squibb Company

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.